# A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer

Source: https://onco.cc/trials/nct07000305/  
OnCo record `nct07000305` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Tao Zhang, not yet recruiting.

## Summary

A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer is a phase 2, interventional study registered as NCT07000305 by Tao Zhang, with a registry enrolment figure of 42 participants, started 2025-05-20 and due to reach its primary completion in 2027-05-20. Interventions recorded: Cetuximabβ combined with Envolimab and mFOLFOX6. Conditions listed: Advanced Colorectal Cancer. Primary outcome: Progression-free survival (PFS). Colorectal eligibility wording from the registry: "Histologically or cytologically confirmed RAS and BRAF wild-type, MSS type colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: SUPβORT
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07000305
- Phase: 2
- Setting: Cetuximabβ Combined With Envolimab and mFOLFOX6 as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable , Metastatic Colorectal Cancer: A Single-arm, Multi-center, Phase II Trail
- Sponsor: Tao Zhang
- Enrolled: 42

## Sources

- ClinicalTrials.gov NCT07000305: https://clinicaltrials.gov/study/NCT07000305

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07000305.json